BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34304246)

  • 21. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of the let-7b microRNA pathway by DNA hypermethylation in infant acute lymphoblastic leukemia with MLL gene rearrangements.
    Nishi M; Eguchi-Ishimae M; Wu Z; Gao W; Iwabuki H; Kawakami S; Tauchi H; Inukai T; Sugita K; Hamasaki Y; Ishii E; Eguchi M
    Leukemia; 2013 Feb; 27(2):389-97. PubMed ID: 22918121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.
    Mata JF; Scrideli CA; Queiroz RP; Mori BO; Emerenciano M; Pombo-de-Oliveira MS; Tone LG
    Braz J Med Biol Res; 2006 Nov; 39(11):1417-23. PubMed ID: 17146554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].
    Nasedkina TV; Ikonnikova AY; Tsaur GA; Karateeva AV; Ammour YI; Avdonina MA; Karachunskii AI; Zasedatelev AS
    Mol Biol (Mosk); 2016; 50(6):968-977. PubMed ID: 28064313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
    Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
    Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
    Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
    Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia.
    Koh K; Tomizawa D; Moriya Saito A; Watanabe T; Miyamura T; Hirayama M; Takahashi Y; Ogawa A; Kato K; Sugita K; Sato T; Deguchi T; Hayashi Y; Takita J; Takeshita Y; Tsurusawa M; Horibe K; Mizutani S; Ishii E
    Leukemia; 2015 Feb; 29(2):290-6. PubMed ID: 24888273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
    Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.
    Urtishak KA; Edwards AY; Wang LS; Hudome A; Robinson BW; Barrett JS; Cao K; Cory L; Moore JS; Bantly AD; Yu QC; Chen IM; Atlas SR; Willman CL; Kundu M; Carroll AJ; Heerema NA; Devidas M; Hilden JM; Dreyer ZE; Hunger SP; Reaman GH; Felix CA
    Blood; 2013 Apr; 121(14):2689-703. PubMed ID: 23393050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homozygous inv(11)(q21q23) and MLL gene rearrangement in two patients with myeloid neoplasms.
    Tang G; Lu X; Wang SA; Roney EK; Zhang L; Hu S; Lu G; Medeiros LJ; Patel A
    Int J Clin Exp Pathol; 2014; 7(6):3196-201. PubMed ID: 25031740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
    Rice S; Roy A
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HOXA9/IRX1 expression pattern defines two subgroups of infant MLL-AF4-driven acute lymphoblastic leukemia.
    Symeonidou V; Ottersbach K
    Exp Hematol; 2021 Jan; 93():38-43.e5. PubMed ID: 33069783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.
    Sison EA; Rau RE; McIntyre E; Li L; Small D; Brown P
    Br J Haematol; 2013 Mar; 160(6):785-97. PubMed ID: 23294096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.